In conclusion, the present study identifies 3d as a potential therapeutic drug molecule for the treatment of MASH, with a mechanism involving the regulation of lipid metabolism, inflammatory response, and apoptosis via the PPAR pathway (Figure 10). The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatohepatitis.